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ACE2

:   angiotensin‐converting enzyme 2

ALT

:   alanine aminotransferase

APTT

:   activated partial thromboplastin time

AS

:   anal swab

AST

:   aspartate aminotransferase

bpm

:   beats per minute

COVID‐19

:   coronavirus disease 2019

Ct

:   cycle threshold

ECMO

:   extracorporeal membrane oxygenation

FiO2

:   oxygen concentration

GI

:   gastrointestinal

HR

:   hazard ratio

ICU

:   intensive care unit

IQR

:   interquartile range

LPV/r

:   lopinavir/ritonavir

N

:   nucleocapsid protein

ORF1ab

:   open reading frame 1ab

PaO2

:   oxygen partial pressure

RNA

:   ribonucleic acid

RT‐PCR

:   reverse‐transcriptase polymerase chain reaction

SARS‐CoV‐2

:   severe acute respiratory syndrome coronavirus 2

SOFA

:   sequential organ failure assessment

SaO2

:   oxygen saturation

TS

:   throat swab

1. BACKGROUND {#jmv26307-sec-0050}
=============

During the last few months, coronavirus disease 2019 (COVID‐19) has become a global public health threat and caused millions of infections and deaths.[^1^](#jmv26307-bib-0001){ref-type="ref"} Research has revealed that the pathogen is a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), belonging to the same family of viruses responsible for the SARS and the Middle East respiratory syndrome (MERS).[^2^](#jmv26307-bib-0002){ref-type="ref"}, [^3^](#jmv26307-bib-0003){ref-type="ref"}, [^4^](#jmv26307-bib-0004){ref-type="ref"} Although most cases are mild with a good prognosis, the mortality rate of severe patients is considerable.[^5^](#jmv26307-bib-0005){ref-type="ref"} At present, no vaccines or specific antiviral drugs are available for prevention or treatment of COVID‐19. Early differentiation of severe cases from mild cases is very helpful to reduce the mortality rate. However, effective early warning indicators of severe disease are still lacking so far.

SARS‐CoV‐2 RNA can be detected not only in the respiratory tract, but also in the blood, digestive tract, and feces.[^6^](#jmv26307-bib-0006){ref-type="ref"}, [^7^](#jmv26307-bib-0007){ref-type="ref"}, [^8^](#jmv26307-bib-0008){ref-type="ref"} Several studies have found that the positive rate of SARS‐CoV‐2 RNA in anal swabs (AS) is higher than that in nasopharyngeal swabs and sputum samples during convalescence,[^9^](#jmv26307-bib-0009){ref-type="ref"}, [^10^](#jmv26307-bib-0010){ref-type="ref"}, [^11^](#jmv26307-bib-0011){ref-type="ref"} suggesting that SARS‐CoV‐2 might actively infect and replicate in the gastrointestinal (GI) tract.[^12^](#jmv26307-bib-0012){ref-type="ref"} Wong et al[^13^](#jmv26307-bib-0013){ref-type="ref"} found patients with more severe disease tended to have a higher detection rate of fecal SARS‐CoV‐2 RNA. Our previous study suggests that detectable SARS‐CoV‐2 RNA in blood is an indicator of further clinical severity.[^14^](#jmv26307-bib-0014){ref-type="ref"} So, the relationship of viral load between the respiratory tract and digestive tract, and its association with the severity of the disease is still unclear.

In this study, we aimed to characterize the longitudinal test results for SARS‐CoV‐2 RNA in the digestive tract and to explore the association between detectable viral RNA and disease severity in patients with COVID‐19.

2. METHODS {#jmv26307-sec-0060}
==========

2.1. Study population {#jmv26307-sec-0070}
---------------------

Guangzhou Eighth People\'s Hospital is one of the designated hospitals for patients with COVID‐19 and hospitalized around 85% of the confirmed cases in Guangzhou. All patients were diagnosed with COVID‐19 by means of reverse‐transcriptase polymerase chain reaction (RT‐PCR) assayed in throat swabs (TSs) before hospitalization, according to World Health Organization interim guidance and the new coronavirus pneumonia prevention and control program (in Chinese).[^15^](#jmv26307-bib-0015){ref-type="ref"}, [^16^](#jmv26307-bib-0016){ref-type="ref"} We retrospectively included laboratory‐confirmed cases with COVID‐19 from 20 January to 20 February 2020, and excluded patients who did not have AS tests during hospitalization. Patients were followed up until 1 June 2020, or the day when patients recovered and discharged from hospital, or were transferred to the designated hospital for critically ill patients, or died. This study was approved by the Ethics Committee of Guangzhou Eighth People\'s Hospital. Written informed consent was obtained from all screened patients.

2.2. Virological detection {#jmv26307-sec-0080}
--------------------------

TSs and ASs were collected periodically for SARS‐COV‐2 RNA detection. Virological detection was carried out on the platform of Da\'an Gene Corporation, Sun Yat‐sen University, Guangzhou, China. Viral RNA extraction and RT‐PCR were performed following the standard protocol.[^14^](#jmv26307-bib-0014){ref-type="ref"}, [^17^](#jmv26307-bib-0017){ref-type="ref"} Viral RNA was extracted with a Nucleic Acid Isolation Kit on an automatic workstation Smart 32, both being provided by Da\'an Gene Corporation, Sun Yat‐sen University. A 200 μL sample was used for extraction following the standard protocol, and viral RNA was finally eluted with 60 μL elution buffer. RT‐PCR reagent was used following the RNA extraction. Two PCR primer and probe sets, targeting open reading frame 1ab (ORF1ab, forward primer: CCCTGTGGGTTTTACACTTAA; reverse primer: ACGATTGTGCATCAGCTGA; fluorescent probe: 5′‐FAM‐CCGTCTGCGGTATGTGGAAAGGTTATGG‐BHQ1‐3′) and nucleocapsid protein (N, forward primer: GGGGAACTTCTCCTGCTAGAAT; reverse primer: CAGACATTTTGCTCTCAAGCTG; fluorescent probe: 5′‐FAM‐TTGCTGCTGCTTGACAGATT‐TAMRA‐3′) separately, were added into the same reaction.[^18^](#jmv26307-bib-0018){ref-type="ref"}, [^19^](#jmv26307-bib-0019){ref-type="ref"} Positive and negative controls were included for each batch of detection. A cycle threshold value (*C* ~t~ value) of 40 or more for both genes was defined as negative, and a *C* ~t~ value of less than 40 for both genes was defined as positive. Samples with a single *C* ~t~ value less than 40 required confirmation by retesting.

2.3. Data collection {#jmv26307-sec-0090}
--------------------

The medical records, nursing records, and laboratory reports of patients were analyzed to obtain data of demographic status (eg, age and gender), underlying comorbidities (eg, diabetes, hypertension, and cardiovascular disease), epidemiological characteristics (eg, recent exposure history), clinical symptoms and signs (eg, fever, cough, and dyspnea), laboratory findings (eg, complete blood count, coagulation test, and blood chemistry), chest computed tomographic scans and treatment measures (eg, antiviral therapy, corticosteroid therapy, and respiratory support). Data were entered into a computerized database and reviewed by a trained team of physicians.

2.4. Definition {#jmv26307-sec-0100}
---------------

On the basis of the new coronavirus pneumonia prevention and control program promulgated by the National Health Commission of China, patients were divided into four clinical classifications.[^16^](#jmv26307-bib-0016){ref-type="ref"} Mild status was defined as having mild clinical symptoms but no signs of pneumonia on imaging. Moderate status was defined as having fever and respiratory symptoms, and/or signs of pneumonia on imaging. Severe status must meet any of the following conditions (a) respiratory rate (RR)≥ 30 breaths/min; (b) finger oxygen saturation (SaO~2~) at rest ≤93%; (c) arterial blood oxygen partial pressure (PaO~2~)/oxygen concentration (FiO~2~) ≤300 mm Hg (1mm Hg = 0.133kPa). Critical status must meet any of the following conditions: (a) respiratory failure requiring mechanical ventilation; (b) shock; (c) patients with another organ functional failure need to be admitted to intensive care unit (ICU) for treatment.

2.5. Statistical analysis {#jmv26307-sec-0110}
-------------------------

Data were expressed as counts and percentages for categorical variables and as mean and standard deviation or median and interquartile range (IQR) for continuous variables. Qualitative and quantitative differences between subgroups were analyzed using the *χ* ^2^ test or Fisher\'s exact tests for categorical parameters and Student *t* test or Mann‐Whitney test for continuous parameters, as appropriate. Cox regression models were performed to evaluate the association between baseline parameters and ICU admission. The log‐rank test was performed to examine differences in the risk of ICU admission. All statistical tests were two‐sided. Statistical significance was taken as *P* \< .05. All analyses were performed with SPSS software, version 26.0 (IBM, Armonk, NY).

3. RESULTS {#jmv26307-sec-0120}
==========

3.1. Patient characteristics {#jmv26307-sec-0130}
----------------------------

From 20 January to 20 February 2020, 297 laboratory‐confirmed patients with COVID‐19 were hospitalized in Guangzhou Eighth People\'s Hospital. After excluding 80 patients who did not receive AS tests during hospitalization, 217 patients were included in this study. The median age was 50 years (IQR, 36‐63), 109 (50.2%) were female and 148 (68.2%) were imported cases. The median duration from disease onset to hospital admission was 4 days (IQR, 2‐7). Ninty (41.5%) patients had one or more comorbidities including hypertension (49 \[22.6%\]), diabetes (17 \[7.8%\]), cardiovascular disease (9 \[4.1%\]), chronic liver disease (15 \[6.9%\]), chronic kidney disease (5 \[2.3%\]), pulmonary tuberculosis (3 \[1.4%\]), and other comorbidities (28 \[12.8%\]). AS tests for SARS‐CoV‐2 RNA were performed at a median of 8 days (QIR, 4‐19) after admission, and the results indicated 21.2% (46/217) of patients were detectable. A total of 52 (24.0%) patients presented with at least one GI symptoms on admission, including anorexia (38 \[17.5%\]), diarrhea (17 \[7.8%\]), nausea (9 \[4.1%\]), vomiting (4 \[1.8%\]), and abdominal pain (3 \[1.4%\]). During hospitalization, 66 (30.4%) patients had occurrence of GI symptoms, including anorexia (33 \[15.2%\]), diarrhea (30 \[13.8%\]), abdominal pain (12 \[5.5%\]), nausea (3 \[1.4%\]), and vomiting (2 \[0.9%\]). The prevalence of GI symptoms that occurred during hospitalization was higher in patients with detectable than those with undetectable SARS‐CoV‐2 RNA in ASs (47.8% vs 25.7%, *P* = .004). The difference was mainly contributed by anorexia (26.1% vs 12.3%, *P* = .021) and diarrhea (21.7% vs 11.7%, *P* = .080). Patients with detectable SARS‐CoV‐2 RNA in ASs had higher levels of systolic and diastolic blood pressure and higher proportions of hypertension (34.8% vs 19.3%, *P* = .026) compared with those with undetectable tests. Other comorbidities like diabetes (6.5% vs 8.2%, *P* = .709), cardiovascular disease (6.5% vs 3.5%, *P* = .363), chronic liver disease (6.5% vs 7.0%, *P* = .906), chronic kidney disease (2.2% vs 2.3%, *P* = .947), and pulmonary tuberculosis (2.2% vs 1.2%, *P* = .512) were comparable between these two groups. Other characteristics between them are shown in Table [1](#jmv26307-tbl-0001){ref-type="table"}. In brief, the demographic status, epidemiological characteristics, clinical symptoms and signs, laboratory and imaging findings, and treatments were comparable between the two groups.

###### 

Characteristics of patients with COVID‐19, according to SARS‐CoV‐2 RNA detection in anal swabs[^a^](#jmv26307-tbl1-note-0002){ref-type="fn"}

  Characteristics                                                       All patients (n = 217)   AS detectable (n = 46)   AS undetectable (n = 171)   *P* value[^b^](#jmv26307-tbl1-note-0003){ref-type="fn"}
  --------------------------------------------------------------------- ------------------------ ------------------------ --------------------------- ---------------------------------------------------------
  Age, y                                                                50 (36‐63)               53 (41‐62)               48 (34‐63)                  .711
  Female sex, n (%)                                                     109 (50.2)               20 (43.5)                89 (52.0)                   .302
  Cases imported from Hubei, n (%)                                      148 (68.2)               33 (71.7)                115 (67.3)                  .562
  Any comorbidity, n (%)                                                90 (41.5)                23 (50.0)                67 (39.2)                   .186
  Days from illness onset to admission (day)                            4 (2‐7)                  4 (2‐6)                  5 (2‐7)                     .237
  Symptoms on admission                                                                                                                               
  Fever, n (%)                                                          155 (71.4)               33 (71.7)                122 (71.3)                  .958
  Highest temperature (°C)                                              38.1 (37.6‐38.7)         38.0 (37.5‐38.8)         38.1 (37.7‐38.6)            .907
  Cough, n (%)                                                          131 (60.4)               31 (67.4)                100 (58.5)                  .273
  Sputum production, n (%)                                              67 (30.9)                17 (37.0)                50 (29.2)                   .315
  Dyspnea, n (%)                                                        29 (13.4)                9 (19.6)                 20 (11.7)                   .164
  GI symptoms, n (%)                                                    52 (24.0)                10 (21.7)                42 (24.6)                   .691
  Diarrhea, n (%)                                                       17 (7.8)                 3 (6.5)                  14 (8.2)                    .709
  Abdominal pain, n (%)                                                 3 (1.4)                  1 (2.2)                  2 (1.2)                     .512
  Anorexia, n (%)                                                       38 (17.5)                7 (15.2)                 31 (18.1)                   .645
  Nausea, n (%)                                                         9 (4.1)                  2 (4.3)                  7 (4.1)                     .939
  Vomiting, n (%)                                                       4 (1.8)                  0 (0.0)                  4 (2.3)                     .581
  Other symptoms[^c^](#jmv26307-tbl1-note-0004){ref-type="fn"}, n (%)   93 (42.9)                18 (39.1)                75 (43.9)                   .565
  GI symptoms occurred during hospitalization, n (%)                    66 (30.4)                22 (47.8)                44 (25.7)                   .004
  Diarrhea, n (%)                                                       30 (13.8)                10 (21.7)                20 (11.7)                   .080
  Abdominal pain, n (%)                                                 12 (5.5)                 2 (4.3)                  10 (5.8)                    .693
  Anorexia, n (%)                                                       33 (15.2)                12 (26.1)                21 (12.3)                   .021
  Nausea, n (%)                                                         3 (1.4)                  1 (2.2)                  2 (1.2)                     .512
  Vomiting, n (%)                                                       2 (0.9)                  1 (2.2)                  1 (0.6)                     .380
  Vital signs on admission                                                                                                                            
  Respiratory rate (bpm)                                                20 (18‐20)               20 (18‐20)               20 (18‐20)                  .464
  Heart rate (bpm)                                                      84 (78‐95)               85 (79‐94)               84 (78‐97)                  .910
  Systolic pressure (mm Hg)                                             126 (118‐138)            130 (122‐143)            125 (117‐137)               .035
  Diastolic pressure (mm Hg)                                            82 (75‐90)               85 (76‐94)               80 (74‐89)                  .037
  Laboratory findings                                                                                                                                 
  C‐reactive protein (mg/L)                                             10 (10‐30)               10 (10‐24)               10 (10‐31)                  .439
  C‐reactive protein ≥10 mg/L, n (%)                                    90 (41.5)                18 (39.1)                72 (42.1)                   .716
  Procalcitonin (ng/mL)                                                 0.04 (0.03‐0.09)         0.05 (0.04‐0.11)         0.04 (0.03‐0.09)            .440
  \<0.05 ng/mL, n (%)                                                   90/153 (58.8)            15/31 (48.4)             75/122 (61.5)               .419
  ≥0.05 to \<0.10 ng/mL, n (%)                                          28/153 (18.3)            8/31 (25.8)              20/122 (16.4)               ...
  ≥0.10 to \<0.50 ng/mL, n (%)                                          33/153 (21.6)            8/31 (25.8)              25/122 (20.5)               ...
  ≥0.50 ng/mL, n (%)                                                    2/153 (0.1)              0/31 (0.0)               2/122 (1.6)                 ...
  Leukopenia, n (%)                                                     46/192 (24.0)            8/41 (19.5)              38/151 (25.2)               .452
  Neutropenia, n (%)                                                    32/192 (16.7)            7/41 (17.1)              25/151 (16.6)               .937
  Lymphocytes (10^9^/L)                                                 1.3 (1.0‐1.9)            1.3 (0.9‐1.6)            1.4 (1.0‐1.9)               .832
  \<0.5 10^9^/L, n (%)                                                  8/192 (4.2)              4/41 (9.8)               4/151 (2.6)                 .116
  ≥0.5 to \<1.0 10^9^/L, n (%)                                          44/192 (22.9)            10/41 (24.4)             34/151 (22.5)               ...
  ≥1.0 10^9^/L, n (%)                                                   140/192 (72.9)           27/41 (65.9)             113/151 (74.8)              ...
  Thrombocytopenia, n (%)                                               27/192 (14.1)            7/41 (17.1)              20/151 (13.2)               .532
  Prothrombin time, s                                                   13.5 (13.1‐14.0)         13.5 (13.1‐13.9)         13.5 (13.1‐14.1)            .646
  APTT, s                                                               39.8 (36.5‐42.6)         41.2 (37.4‐43.6)         40.0 (36.7‐44.2)            .296
  Total bilirubin, μmol/L                                               9 (7‐14)                 10 (7‐13)                9 (7‐14)                    .532
  Albumin, g/L                                                          40 (36‐43)               40 (36‐44)               40 (37‐42)                  .739
  ALT elevation, n (%)                                                  26/197 (13.2)            7/39 (17.9)              19/148 (12.8)               .412
  AST elevation, n (%)                                                  31/190 (16.3)            8/40 (20.0)              23/150 (15.3)               .478
  Increased creatinine, n (%)                                           34/183 (18.6)            9/37 (24.3)              25/146 (17.1)               .314
  Increased creatine kinase, n (%)                                      20/179 (11.1)            6/38 (15.8)              14/141 (9.9)                .309
  Lactate dehydrogenase, U/L                                            193 (153‐246)            187 (150‐290)            194 (153‐244)               .787
  Imaging findings                                                                                                                                    
  Pneumonia, n (%)                                                      179 (82.5)               35 (76.1)                144 (84.2)                  .198
  Hydrothorax, n (%)                                                    13/208 (6.3)             1/44 (2.3)               12/164 (7.3)                .220
  Pulmonary consolidation, n (%)                                        18/208 (8.7)             1/44 (2.3)               17/164 (10.4)               .090
  Treatment                                                                                                                                           
  Oxygen inhalation, n (%)                                              145 (66.8)               29 (63.0)                116 (67.8)                  .540
  Antibacterial agents, n (%)                                           142 (65.4)               29 (63.0)                113 (66.1)                  .700
  Anticoronavirus treatment                                                                                                                           
  LPV/r, n (%)                                                          77 (35.5)                21 (45.7)                56 (32.7)                   .104
  Arbidol, n (%)                                                        93 (42.9)                18 (39.1)                75 (43.9)                   .565
  Chloroquine phosphate, n (%)                                          29 (13.4)                5 (10.9)                 24 (14.0)                   .575
  Oseltamivir, n (%)                                                    57 (26.3)                17 (37.0)                40 (23.4)                   .063
  Glucocorticoid, n (%)                                                 42 (19.4)                7 (15.2)                 35 (20.5)                   .424
  Immunoglobulin, n (%)                                                 28 (12.9)                6 (13.0)                 22 (12.9)                   .975

Abbreviations: APTT, activated partial thromboplastin time; ALT, alanine aminotransferase; AS, anal swabs; AST aspartate aminotransferase; bpm, beats per minute; COVID, novel coronavirus (SARS‐CoV‐2)‐infected disease; GI, gastrointestinal; IQR, interquartile range; LPV/r, lopinavir/ritonavir.

Data are presented as medians (IQR) or n (%). The increase and decrease of laboratory indicators are compared with the normal range of local laboratory testing.

Qualitative and quantitative differences were analyzed using the *χ* ^2^ test or Fisher\'s exact tests for categorical parameters and the Student *t* test or Mann‐Whitney test for continuous parameters, as appropriate. All statistical tests were two‐sided.

Other symptoms included myalgia, fatigue, sore throat, and headache.
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3.2. Longitudinal change of AS tests {#jmv26307-sec-0140}
------------------------------------

The longitudinal changes of SARS‐CoV‐2 RNA in ASs and TSs among the 46 patients who had detectable viral RNA in ASs are shown in Figure [1](#jmv26307-fig-0001){ref-type="fig"}. Most patients were tested for viral RNA in ASs at intervals of 3 to 6 days. Fifteen patients had AS tests within 3 days after admission, among which 11 presented positive for viral RNA. The median duration from admission to the negative conversion of viral RNA was longer in ASs than in TSs (19 days vs 11 days, *P* = .007). Seventeen (37.0%) patients presented detectable viral RNA in ASs after negative conversion in TSs. Thirteen (28.3%) and 9 (19.6%) out of the 46 patients remained viral RNA detectable in ASs for up to 3 and 4 weeks after admission, respectively. The median cycle threshold (*C* ~t~) values (*C* ~t~ = ORF1ab + N) of the AS tests on admission, week 1, week 2, and week 3 were (*C* ~t~ = 39 + 37), (*C* ~t~ = 39 + 37), (*C* ~t~ = 39 + 38), and (*C* ~t~ = 39.5 + 38), respectively. The median *C* ~t~ values of the throat swab tests on admission, week 1, week 2, and week 3 were (*C* ~t~ = 34 + 31.5), (*C* ~t~ = 35.5 + 34), (*C* ~t~ = 39 + 36.5), and (*C* ~t~ = 38.5 + 35.5), respectively. The *C* ~t~ values of the ORF1ab genes in AS tests were higher than those in throat swab tests on admission (39 vs 34, *P* = .010) and week 1 (39 vs 35.5, *P* = .069) (Figure [2A](#jmv26307-fig-0002){ref-type="fig"}), although not all the differences are statistically significant. Similarly, the *C* ~t~ values of the N genes in AS tests tended to be higher than those in throat swab tests on admission (37 vs 31.5, *P* = .078) and week 1 (37 vs 34, *P* = .056) (Figure [2B](#jmv26307-fig-0002){ref-type="fig"}). One week after admission, there was no difference in the *C* ~t~ values between ASs and TSs (Figure [3](#jmv26307-fig-0003){ref-type="fig"}).

![Longitudinal results of anal swabs and throat swabs among the 46 patients with detectable SARS‐CoV‐2 RNA in the anal swab](JMV-9999-na-g001){#jmv26307-fig-0001}

![Cumulative incidence of intensive care unit (ICU) admission in patients with detectable and undetectable SARS‐CoV‐2 RNA in the anal swab](JMV-9999-na-g002){#jmv26307-fig-0002}

![Comparision of longitudinal cycle threshold (*C* ~t~) values between anal swabs (AS) and throat swabs (TS). A, *C* ~t~ values of the open reading frame 1ab (ORF1ab) genes. B, *C* ~t~ values of the nucleocapsid protein (N) genes](JMV-9999-na-g003){#jmv26307-fig-0003}

3.3. Disease severity and clinical outcomes {#jmv26307-sec-0150}
-------------------------------------------

Of the 217 hospitalized patients with COVID‐19, 201 (92.6%) patients were diagnosed with mild/moderate status, and 16 (7.4%) severe/critical status on admission. During a median follow‐up of 20 days (IQR, 14‐26), 174 (80.2%) patients were diagnosed with mild/moderate status, and 43 (19.8%) severe/critical status. A total of 30 (13.8%) patients were admitted to ICU for high‐flow nasal cannula or higher‐level oxygen support measures to correct hypoxemia, among whom 12 (5.5%) patients needed mechanical ventilation and 4 (1.8%) patients used extracorporeal membrane oxygenation (ECMO). 3.7% (8/217) patients were transferred to the designated hospital for critically ill patients in Guangzhou due to the deterioration of their illness. Only one (0.5%) patient (82‐year‐old male) died of multiple organ failure even though receiving ECMO treatment. As of 1 June 2020, all the remaining 208 (95.9%) patients had recovered and were discharged from Guangzhou Eighth People\'s hospital.

The disease severity and clinical outcomes between patients with detectable and undetectable SARS‐CoV‐2 RNA in ASs are shown in Table [2](#jmv26307-tbl-0002){ref-type="table"}. The proportion of ICU admission was higher in the detectable group than the undetectable group (26.1% vs 10.5%, *P* = .007). In addition, patients with detectable viral RNA in ASs had a higher trend of severe/critical status (on admission, 13.0% vs 5.8%, *P* = .097) and mechanical ventilation (10.9% vs 4.1%, *P* = .074). Patients with detectable viral RNA in ASs had significantly longer duration from admission to positive‐to‐negative conversion of TSs viral RNA (11 days vs 8 days, *P* = .027) and hospitalization stay (22 days vs 20 days, *P* = .031).

###### 

Disease severity and clinical outcomes of the studied patients

  Variables[^a^](#jmv26307-tbl2-note-0002){ref-type="fn"}                             All patients (n = 217)   AS detectable (n = 46)   AS undetectable (n = 171)   *P* value
  ----------------------------------------------------------------------------------- ------------------------ ------------------------ --------------------------- -----------
  Clinical classifications on admission                                                                                                                             
  Mild/moderate status, n (%)                                                         201 (92.6)               40 (87.0)                161 (94.2)                  .097
  Severe/critical status, n (%)                                                       16 (7.4)                 6 (13.0)                 10 (5.8)                    ...
  Clinical classifications during hospitalization                                                                                                                   
  Mild/moderate status, n (%)                                                         174 (80.2)               34 (73.9)                140 (81.9)                  .229
  Severe/critical status, n (%)                                                       43 (19.8)                12 (26.1)                31 (18.1)                   ...
  Admitted to ICU, n (%)                                                              30 (13.8)                12 (26.1)                18 (10.5)                   .007
  Mechanical ventilation, n (%)                                                       12 (5.5)                 5 (10.9)                 7 (4.1)                     .074
  Use of ECMO, n (%)                                                                  4 (1.8)                  1 (2.2)                  3 (1.8)                     1.000
  Duration from admission to positive‐to‐negative conversion of TS viral RNA (days)   8 (5‐13)                 11 (7‐16)                8 (5‐12)                    .027
  Duration from admission to improvement of pneumonia (days)                          8 (7‐14)                 11 (7‐18)                8 (6‐13)                    .067
  Outcomes                                                                                                                                                          
  Transferred for advanced treatment, n (%)                                           8 (3.7)                  4 (8.7)                  4 (2.3)                     .021
  Death, n (%)                                                                        1 (3.7)                  1 (2.2)                  0 (0.0)                     ...
  Recovered and discharge from hospital, n (%)                                        208 (95.9)               41 (89.1)                167 (97.7)                  ...
  Duration of hospitalization (days)[^b^](#jmv26307-tbl2-note-0003){ref-type="fn"}    20 (14‐26)               22 (18‐30)               20 (13‐26)                  .031

Abbreviations: AS, anal swabs; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; TS, throat swabs.

Data are presented as medians (IQR) or n (%).

The calculation of the duration of hospitalization excluded the eight patients who were transferred to the designated hospital for advanced treatment.
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3.4. Factors associated with ICU admission {#jmv26307-sec-0160}
------------------------------------------

Table [3](#jmv26307-tbl-0003){ref-type="table"} shows the factors associated with ICU admission during hospitalization. In the univariate Cox regression analysis, age (\>60 vs ≤60 years), sex (male vs female), comorbidity (yes vs no), GI symptoms throughout the hospitalization (yes vs no), detectable viral RNA in ASs (yes vs no), C‐reactive protein (\>10 vs ≤10 mg/L) and lymphocyte count (≤1.0 vs \>1.0 × 10^9^/L) were associated with ICU admission. In multivariate analysis, detectable viral RNA in ASs (adjusted hazard ratio \[aHR\], 2.50; 95% confidence interval \[CI\], 1.20‐5.24, *P* = .015), C‐reactive protein (aHR, 3.14; 95% CI, 1.35‐7.32, *P* = .008), and lymphocyte count (aHR, 3.12; 95% CI, 1.46‐6.67, *P* = .003) were independently associated with ICU admission. The 7‐day and 14‐day cumulative incidence of ICU admission was 23.9% and 26.3% among patients with detectable RNA in ASs, and 8.8% and 10.7% among patients with undetectable RNA in ASs, respectively. The 21‐day cumulative incidence of ICU admission was higher among patients with detectable RNA in ASs than patients with undetectable RNA (26.3% vs 10.7%, *P* = .006) (Figure [3](#jmv26307-fig-0003){ref-type="fig"}).

###### 

Factors associated with ICU admitted among patients with COVID‐19

                                                                          Admitted to ICU                                
  ----------------------------------------------------------------------- ------------------ -------- ------------------ ------
  Age (\>60 vs ≤60 y)                                                     2.12 (1.04‐4.34)   .040                        
  Sex (male vs female)                                                    2.16 (1.01‐4.61)   .047                        
  Comorbidity (yes vs no)                                                 3.02 (1.41‐6.45)   .004                        
  GI symptoms[^b^](#jmv26307-tbl3-note-0003){ref-type="fn"} (yes vs no)   2.55 (1.17‐5.56)   .019                        
  Detectable viral RNA in AS (yes vs no)                                  2.64 (1.27‐5.49)   .009     2.50 (1.20‐5.24)   .015
  C‐reactive protein (\>10 vs ≤10 mg/L)                                   4.15 (1.85‐9.31)   .001     3.14 (1.35‐7.32)   .008
  Lymphocyte count (≤1.0 vs \>1.0 × 10^9^/L)                              4.57 (2.22‐9.42)   \<.001   3.12 (1.46‐6.67)   .003

Abbreviations: AS, anal swabs; GI, gastrointestinal; HR, hazard ratio; ICU, intensive care unit.

Factors associated with ICU admission were analyzed by the Cox regression model (forward stepwise).

GI symptoms including presence on admission and new occurrences during hospitalization.
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4. DISCUSSION {#jmv26307-sec-0170}
=============

This study found that 21.2% of COVID‐19 patients were detectable for SARS‐CoV‐2 RNA in ASs, and longer duration with lower levels of the virus was found in ASs than in TSs. Patients with detectable viral RNA in ASs had a significantly higher risk of ICU admission. These findings may provide critical information for quickly establishing a COVID‐19 hierarchical management system that can greatly reduce the development of severe disease and mortality rates.

The demographic characteristics, clinical symptoms, laboratory index, and imaging findings were not different between patients with ASs positive and those with negative results. However, we found that patients with detectable viral RNA in ASs were more likely to develop GI symptoms such as anorexia and diarrhea. A recent study involving 84 hospitalized health care workers with COVID‐19 found the positive rate of viral RNA in stool samples was higher in patients with diarrhea than those without diarrhea (69% vs 17%, *P* \< .001).[^20^](#jmv26307-bib-0020){ref-type="ref"} These pieces of evidence together indicate that intestinal infection of novel coronavirus is related to the GI symptoms in COVID‐19 patients.

A recent study has found that angiotensin‐converting enzyme 2 (ACE2) is the receptor for SARS‐CoV‐2 attachment and entry.[^3^](#jmv26307-bib-0003){ref-type="ref"} Besides the lung, ACE2 is also present in the epithelia of the small intestine and endothelial cells.[^21^](#jmv26307-bib-0021){ref-type="ref"}, [^22^](#jmv26307-bib-0022){ref-type="ref"} In addition, SARS‐CoV‐2 RNA has been found in patient feces, and Lu et al further found viral RNA exists in the esophagus, stomach, duodenum, and rectum specimens.[^8^](#jmv26307-bib-0008){ref-type="ref"}, [^23^](#jmv26307-bib-0023){ref-type="ref"} In this study, we found over one in five patients were detected with viral RNA in ASs. Liu et al observed four patients had detectable SARS‐CoV‐2 RNA by RT‐PCR in ASs from 69 patients who had recovered from COVID‐19. Among these four patients, three had positive results in nasopharyngeal swabs, and the positive results on the respiratory tract were observed before the digestive tract.[^24^](#jmv26307-bib-0024){ref-type="ref"} Kipkorir et al summed up the recent evidence of prolonged SARS‐CoV‐2 detection in anal/rectal swabs and stool specimens in COVID‐19 patients after negative conversion in nasopharyngeal RT‐PCR test and found that the pooled prevalence estimate for prolonged rectal/anal/stool SARS‐CoV‐2 RNA was 32%, highlighting the potential of GI shedding of the virus even in asymptomatic patients.[^25^](#jmv26307-bib-0025){ref-type="ref"} Peng et al detected SARS‐CoV‐2 RNA in urine and blood specimens and anal and oropharyngeal swabs. Although they found symptoms related to infection of these systems may not be present, they still believed testing different specimen types may be useful for monitoring disease changes and progression, and for establishing a prognosis.[^26^](#jmv26307-bib-0026){ref-type="ref"} Our longitudinal study found a positive coloration between ASs and disease severity, further supporting their conclusion. Consistent with previous reports,[^9^](#jmv26307-bib-0009){ref-type="ref"}, [^10^](#jmv26307-bib-0010){ref-type="ref"}, [^27^](#jmv26307-bib-0027){ref-type="ref"} we found the duration of viral was longer in ASs than in TSs, suggesting persistent fecal viral shedding and potential fecal‐oral transmission.

The transmission ability of the virus is greatly correlated with the viral load. However, little is known about the viral load of SARS‐CoV‐2 in the digestive tract. In this study, we found the *C* ~t~ values were higher in ASs than those in TSs in the early stages of COVID‐19. The high Ct values in ASs approximately indicated low levels of virus in these specimens.[^11^](#jmv26307-bib-0011){ref-type="ref"} In the middle and later stages of the disease, there was no significant difference in viral load between them, and both tended to be negative. It is suggested that during the recovery period of the disease, the virus in the respiratory tract and digestive tract are gradually eliminated. However, it is still uncertain when the patient will not be contagious. As we only detected the viral RNA but could not isolate the live virus, the transmission ability among these patients is still unclear. One of the limitations of PCR testing is the inability to differentiate between actual viral replication and the detection of nonviable, and therefore noninfectious, viral material.[^28^](#jmv26307-bib-0028){ref-type="ref"}

The novel finding of this study was the association between AS test results for SARS‐CoV‐2 RNA and disease severity. Patients with detectable viral RNA in ASs had a higher cumulative incidence of ICU admission, a sign of disease deterioration. After adjusting for known risk factors including age, sex, comorbidities, GI symptoms, C‐reactive protein, and lymphocyte count, this study showed that detectable viral RNA in ASs was independently associated with ICU admission. Patients with detectable viral RNA in ASs had a 2.5 times higher risk of ICU admission than those with detectable viral RNA in ASs. Our previous small sample size, cross‐sectional study found that the presence of viral RNA in the blood was positively correlated with disease severity.[^14^](#jmv26307-bib-0014){ref-type="ref"} The present large sample size and follow‐up study clarified the relationship between viral RNA in the digestive tract and disease severity. Recent studies have suggested that the disease severity may be related to age, concomitant disease, lymphocytes, interleukin‐6, sequential organ failure assessment (SOFA) score, and D‐dimer, but the association with virus distribution is unclear so far.[^29^](#jmv26307-bib-0029){ref-type="ref"}, [^30^](#jmv26307-bib-0030){ref-type="ref"}, [^31^](#jmv26307-bib-0031){ref-type="ref"} Although patients with detectable viral RNA in ASs had a higher proportion of hypertension, further analysis shows that hypertension was not independently associated with ICU admission. This study revealed the relationship between the virus in the digestive tract and the severity of COVID‐19, highlighting the need to screen the virus in the digestive tract.

The reason why patients with viruses in the digestive tract may have more serious diseases remains largely unknown, one of the possible reasons is the rampant coronavirus replication in the pulmonary alveolus. The actively replicating virus may break through the alveolar vessel leakage into the blood flow, and infect the intestinal epithelium. Compared with patients with undetectable viral RNA, patients with detectable viral RNA in ASs had lower *C* ~t~ values in the TSs (median: *C* ~t~ = 34.5 + 36 vs *C* ~t~ = 39 + 40), indicating higher viral load. Another possible reason is delayed virus clearance. As mentioned above, SARS‐CoV‐2 RNA was found in the esophagus, stomach, duodenum, and rectum specimens,[^8^](#jmv26307-bib-0008){ref-type="ref"} due to the large number and wide distribution of ACE2,[^21^](#jmv26307-bib-0021){ref-type="ref"} the digestive tract may serve as an extrapulmonary site for viral replication and storage.[^32^](#jmv26307-bib-0032){ref-type="ref"} These factors may cause delayed elimination of SARS‐CoV‐2 from the respiratory system, leading to disease progression. We found patients who were positive for viral RNA both in TSs and ASs had delayed clearance of virus, delayed improvement of pneumonia, and longer duration of hospitalization than patients who were positive for viral RNA only in TSs, despite having the same treatment strategy. Further verification is needed.

Our study has some limitations. First, this study mainly summarized from clinical phenomena and laboratory test results, the data regarding cytokine storm and viral genome are lacking. Second, in the early stages of the epidemic, paired and serial specimens of TSs and ASs were not obtained at every time point, and the prevalence of detectable viral RNA in ASs could be underestimated. Third, the prevalence of COVID‐19 in Guangzhou is relatively low, and most patients were of non‐severe type. Therefore, the number of patients with a serious disease is limited, and the predictors of this study need to be further verified. Fourth, due to the rapid outbreak of the epidemic, we do not have more details about the patient\'s treatment history. Whether these treatment histories affect the present results needs further investigation.

In summary, we found a longer duration of the virus but lower viral load in the digestive tract than in the respiratory tract, and detectable SARS‐CoV‐2 RNA in the digestive tract was a potential warning indicator of severe disease. Screening the virus in the digestive tract, close monitoring, and early intervention in patients with the detectable virus are needed.
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